Human FGF-23 Biotinylated Antibody

Catalog #: BAF2604 Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
BAF2604

All FGF-23 Antibodies

Product Details

Supplemental Products

Reviews

Summary Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human FGF-23 Biotinylated Antibody Summary

Species Reactivity

Human

Specificity

Detects human FGF-23 in Western blots. In this format, approximately 20% cross-reactivity with recombinant mouse FGF‑23 is observed.

Source

Polyclonal Goat IgG

Purification

Antigen Affinity-purified

Immunogen

Mouse myeloma cell line NS0-derived recombinant human FGF-23 (R&D Systems, Catalog # 2604-FG)
Tyr25-Ile251
Accession # Q9GZV9

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.

Label

Biotin

Applications

Recommended Concentration

Sample

Western Blot

0.1 µg/mL

Recombinant Human FGF‑23 (Catalog # 2604-FG)

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Reconstitution Calculator

Preparation and Storage

Reconstitution

Reconstitute at 0.2 mg/mL in sterile PBS.

Shipping

The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: FGF-23

Fibroblast growth factor 23 (FGF-23) is a 30-32 kDa member of the FGF family, within a subfamily that also includes FGF-19 and FGF-21. FGF proteins contain a 120 amino acid (aa) core FGF domain that exhibits a beta -trefoil structure (1, 2). FGF-19 subfamily members are highly diffusible molecules owing to their poor ECM/heparin sulfate binding and plasma-stabilizing intramolecular folds (2-4). Mature human FGF-23 contains an atypical (very low affinity) heparin binding site (aa 134‑162), a proteolytic cleavage site (Arg179-Ser180), and multiple O-linked glycosylation sites with Thr178 being of particular importance (4-7). O-linked glycosylation at Thr178 blocks the cleavage of FGF-23, thereby preventing loss of FGF-23 activity (7, 8). Mature human FGF-23 shows 72% aa identity to mouse FGF-23 and is active on mouse cells (6). FGF-23 exerts its effects through a ternary complex that includes Klotho and an FGF receptor (FGF R4 or the "c" isoforms of FGF R1 or FGF R3). Klotho has a restricted distribution that limits FGF-23 activity (9-11). FGF-23 is produced by osteocytes and osteoblasts in response to high circulating phosphate levels, elevated parathyroid hormone, and circulatory volume loading. It functions as an endocrine phosphatonin by suppressing circulating phosphate levels (12). FGF-23 interaction with renal proximal tubular epithelium decreases the renal resorption of phosphate by downregulating phosphate transporters and by suppressing vitamin D production. It also decreases the intestinal absorption of phosphate (13).

References

Mohammadi, M. et al. (2005) Cytokine Growth Factor Rev. 16:107.
Fukumoto, S. (2007) Endocr. J. Sep 14; [Epub ahead of print].
Goetz, R. et al. (2007) Mol. Cell. Biol. 27:3417.
Harmer, N.J. et al. (2004) Biochemistry 43:629.
Yamashita, T. et al. (2000) Biochem. Biophys. Res. Commun. 277:494.
Shimada, T. et al. (2001) Proc. Natl. Acad. Sci. USA 98:6500.
Frishberg, Y. et al. (2007) J. Bone Miner. Res. 22:235.
Kato, K. et al. (2006) J. Biol. Chem. 281:18370.
Zhang, X. et al. (2006) J. Biol. Chem. 281:15694.
Urakawa, I. et al. (2006) Nature 444:770.
Kurosu, H. et al. (2006) J. Biol. Chem. 281:6120.
Razzaque, M.S. and B. Lanske (2007) J. Endocrinol. 194:1.
Kurosu, H. et. al. (2007) J. Biol. Chem. 282:26687.

Long Name

Fibroblast Growth Factor 23

Entrez Gene IDs

8074 (Human); 64654 (Mouse)

Alternate Names

ADHR; FGF23; FGF-23; fibroblast growth factor 23; HPDR2; HYPF; phosphatonin; PHPTC; tumor-derived hypophosphatemia inducing factor; Tumor-derived hypophosphatemia-inducing factor